Antoine Adenis

6PUBLICATIONS
19CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 10, 2024
Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study.

Antoine Adenis, François Ghiringhelli, Ludovic Gauthier

|Aug 15, 2022
Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study.

Thierry André, David Tougeron, Guillaume Piessen

|Jan 07, 2022
Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial.

Marc Ychou, Michel Rivoire, Simon Thezenas

|Nov 03, 2021
Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181.

Antoine Adenis, Amit S Kulkarni, Gustavo C Girotto

|May 18, 2021
FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer.

Antoine Adenis, Thibault Mazard, Julien Fraisse

|May 02, 2021
Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment.

Brice Pastor, Thierry André, Julie Henriques

Pageof 1

Frequent Collaborators

2 joint publications

Thierry André

2 joint publications

Thibault Mazard

2 joint publications

Christelle de la Fouchardiere

2 joint publications

Marc Ychou